# Casgevy

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/casgevy
Canonical HTML page: https://getbiobrief.com/entity/casgevy

## Timeline

- **2026**: Label expansion — FDA expands Casgevy’s indication to include patients as young as two years old, enabling earlier intervention.
- **2023**: Casgevy approval — FDA approves Casgevy for sickle cell disease and transfusion-dependent beta-thalassemia in patients aged 12 and older.

## Recent coverage (2 stories)

### Casgevy Label Expansion and Readouts Could Validate CRISPR's $2.2M Therapy
2026-09-03 00:53:22 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The Casgevy label expansion to ages 2+ broadens the patient pool for the first approved CRISPR therapy. Upcoming clinical readouts may de-risk CRISPR Therapeutics' gene-editing platform beyond rare hemoglobinopathies.
Full story: https://getbiobrief.com/story/crispr-casgevy-label-expansion-clinical-readouts-bio

### Casgevy Wins FDA Nod for Kids 2+, Widening $2.2M Gene Therapy Duel
2026-07-09 07:50:38 · Sentiment: Positive · Impact: 8/10 · Sources: 20

The FDA's expansion of Casgevy to children aged 2–11 solidifies Vertex and CRISPR Therapeutics' lead over bluebird bio’s Lyfgenia, opens a lucrative new patient segment, and validates the safety of CRISPR gene editing in very young patients.
Full story: https://getbiobrief.com/story/crispr-casgevy-pediatric-fda-approval-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.